Natto: Christopher von Schirach-Szmigiel elected as member of the board of directors

Christopher von Schirach-Szmigiel was elected as member of the Board of Directors in NattoPharma ASA for a period of two years at the General Assembly 25th June 2015.  Frode Marc Bohan remains Chairman of the Board as his position was not up for election.  Katrazyna Maresz was elected as Board member for another two-year period.

Christopher von Schirach-Szmigiel is born in Poland and settled in Stockholm. He speaks several languages and is worldwide recognised for his scientific achivements, buisiness skills and abilities to “think out of the box” in strategic positioning of global buisinesses. He is educated within finance and management and has held postions as visiting professor in finance, management and strategic management and leadership among other places at New York University, Stockholm School of Economics, Norges Handelshøyskole, Bergen, Norway and the Pennsylvania State University.

Christopher von Schirach-Szmigiel was Board Director in Uniliver Nordic, Stora Data, Ericsson Group, Audi-Volkswagen Scandinavia and Porsche. He has also served as Board dierector at Universities in Sweden, USA and Poland and has been expert and advisor for the Swedish government in shipping and shipbuilding.

Christopher von Schirach-Szmigiel has the last five years focused his activities on the Board of Directors in companies with commercial oppertunities where he believes his participation can make a difference – through increasing the company growth rate. Christopher von Schirach-Smigiel has been in contact with key people within NattoPharma ASA for the last two years, and has expressed an interest in the company. Through his new position as member of the Board of Directors he will inspire, guide and utilize his global business network as a for NattoPharma ASA ambassadoer.

“The election of Christopher von Schirach-Smigiel as member of the Board of Directors in NattoaPharma ASA is a part of the plan to move NattoPharma from an “entrepreneurial start-up company” within the dietary supplement business segment to a visible player within global biotechnology, neutraceutical and the pharmaceutical field – growing our current business and systematically developing us towards a recognized pharmacuetical company” says Frode M. Bohan, Chairman of the Board in NattoPharma ASA.

“Christopher von Schirach-Smigiel has the strategic vision to move companies to a higher level of knowledge – and states that learning faster than your competitors is the only sustainable competetive advantage. I am looking forward to working with him and together secure growth and create shareholder values”, says Hogne Vik, CEO in NattoPharma.

# # #

About MenaQ7®

MenaQ7® provides natural vitamin K2 as a manufactured fermentation extract. This process generates a highly pure and bio-available form of vitamin K2, menaquinone-7(MK-7). MenaQ7 is the purest and best documented natural vitamin K2 with guaranteed actives and stability, clinical substantiation and several granted patents on cardiovascular health.

About NattoPharma

As a biotechnology-based nutraceutical company, NattoPharma is the worldwide innovator and leader of Vitamin K2 menaquinone-7. Its brand MenaQ7® is supported by a global IPR portfolio and research substantiating clear efficacy for bone and cardiovascular health. NattoPharma has since 2007 been in a research and development collaboration with the University in Maastricht, The Netherlands, working to substantiate the health benefits of vitamin K2.

For more information, please contact:

Hogne Vik,

CEO (+47-97535326

Hogne.vik@nattopharma.com

Tags:

About Us

NattoPharma, the world leader in Vitamin K2 Research and Development, has invested millions of dollars in in-vitro, in-vivo, and clinical studies to document the effects of MenaQ7® Vitamin K2 as MK-7. This commitment has created the only patented and clinically validated K2 on the market. After establishing the first commercial Vitamin K2 with its flagship brand, MenaQ7®, NattoPharma has consistently answered and met market needs through the development of new production technologies:• In 2012, the company introduced MenaQ7® Crystals, which represented an important breakthrough in the new generation of Vitamin K2 products, producing the purest natural MK-7 available.• In 2014, NattoPharma introduced the only all-trans nature-identical synthesized Vitamin K2, MenaQ7® PURE. Not only did the company succeed in changing the market with MenaQ7® PURE – offering a high-quality, competitively priced ingredient – but its efforts were rewarded with the NutrAward for Best Functional Ingredient at Natural Products West/engredea 2015. Vitamin K2 is essential for the body to utilize calcium to build healthy, strong bones and to inhibit calcium deposits in the arteries. Published clinical studies have demonstrated the high bioavailability and proof of efficacy for Nattopharma’s all-trans MK-7 products in healthy and diseased populations, for bone and cardiovascular health. NattoPharma continues to build its competitive advantage through focuson IPR and has patents both granted and pending related to relevant healthbenefits and market segments, creating extra value for its customers. And NattoPharma staff consists of professionals people with longstanding experience in medical and biochemical research as well as pharmaceutical and food supplement development. By understanding and controlling the chemistry, NattoPharma provides the market all-trans MK-7 products, while our sales and marketing team has extensive knowledge of international market demands with which it supports our partners.